- Home
- ORIC vs ATYR Comparison
ORIC vs ATYR Comparison
Compare ORIC & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORIC
- ATYR
- Stock Information
- Founded
- ORIC 2014
- ATYR 2005
- Country
- ORIC United States
- ATYR United States
- Employees
- ORIC N/A
- ATYR N/A
- Industry
- ORIC Biotechnology: Pharmaceutical Preparations
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ORIC Health Care
- ATYR Health Care
- Exchange
- ORIC Nasdaq
- ATYR Nasdaq
- Market Cap
- ORIC 362.9M
- ATYR 290.6M
- IPO Year
- ORIC 2020
- ATYR 2015
- Fundamental
- Price
- ORIC $5.08
- ATYR $3.30
- Analyst Decision
- ORIC Strong Buy
- ATYR Strong Buy
- Analyst Count
- ORIC 8
- ATYR 6
- Target Price
- ORIC $18.83
- ATYR $18.60
- AVG Volume (30 Days)
- ORIC 630.2K
- ATYR 1.1M
- Earning Date
- ORIC 05-05-2025
- ATYR 05-07-2025
- Dividend Yield
- ORIC N/A
- ATYR N/A
- EPS Growth
- ORIC N/A
- ATYR N/A
- EPS
- ORIC N/A
- ATYR N/A
- Revenue
- ORIC N/A
- ATYR N/A
- Revenue This Year
- ORIC N/A
- ATYR $551.06
- Revenue Next Year
- ORIC N/A
- ATYR $2,144.84
- P/E Ratio
- ORIC N/A
- ATYR N/A
- Revenue Growth
- ORIC N/A
- ATYR N/A
- 52 Week Low
- ORIC $3.90
- ATYR $1.42
- 52 Week High
- ORIC $14.67
- ATYR $4.66
- Technical
- Relative Strength Index (RSI)
- ORIC 44.71
- ATYR 52.29
- Support Level
- ORIC $4.52
- ATYR $3.06
- Resistance Level
- ORIC $5.83
- ATYR $3.45
- Average True Range (ATR)
- ORIC 0.52
- ATYR 0.24
- MACD
- ORIC 0.07
- ATYR 0.01
- Stochastic Oscillator
- ORIC 40.58
- ATYR 52.46
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.